IDEAS home Printed from https://ideas.repec.org/a/bla/biomet/v70y2014i2p389-397.html
   My bibliography  Save this article

Simple benchmark for complex dose finding studies

Author

Listed:
  • Ying Kuen Cheung

Abstract

No abstract is available for this item.

Suggested Citation

  • Ying Kuen Cheung, 2014. "Simple benchmark for complex dose finding studies," Biometrics, The International Biometric Society, vol. 70(2), pages 389-397, June.
    • Handle: RePEc:bla:biomet:v:70:y:2014:i:2:p:389-397
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1111/biom.12158
    Download Restriction: Access to full text is restricted to subscribers.
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Cheung, Ying Kuen, 2007. "Sequential Implementation of Stepwise Procedures for Identifying the Maximum Tolerated Dose," Journal of the American Statistical Association, American Statistical Association, vol. 102, pages 1448-1461, December.
    2. Z. Yuan & R. Chappell & H. Bailey, 2007. "The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi-Likelihood Approach," Biometrics, The International Biometric Society, vol. 63(1), pages 173-179, March.
    3. Bekele, B. Nebiyou & Thall, Peter F., 2004. "Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial," Journal of the American Statistical Association, American Statistical Association, vol. 99, pages 26-35, January.
    4. Peter F. Thall & John D. Cook, 2004. "Dose-Finding Based on Efficacy–Toxicity Trade-Offs," Biometrics, The International Biometric Society, vol. 60(3), pages 684-693, September.
    5. Nadine Houede & Peter F. Thall & Hoang Nguyen & Xavier Paoletti & Andrew Kramar, 2010. "Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials," Biometrics, The International Biometric Society, vol. 66(2), pages 532-540, June.
    6. Guosheng Yin & Yisheng Li & Yuan Ji, 2006. "Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios," Biometrics, The International Biometric Society, vol. 62(3), pages 777-787, September.
    7. Ying Kuen Cheung, 2005. "Coherence principles in dose-finding studies," Biometrika, Biometrika Trust, vol. 92(4), pages 863-873, December.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Beibei Guo & Suyu Liu, 2018. "Optimal Benchmark for Evaluating Drug-Combination Dose-Finding Clinical Trials," Statistics in Biosciences, Springer;International Chinese Statistical Association, vol. 10(1), pages 184-201, April.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Nadine Houede & Peter F. Thall & Hoang Nguyen & Xavier Paoletti & Andrew Kramar, 2010. "Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials," Biometrics, The International Biometric Society, vol. 66(2), pages 532-540, June.
    2. Anastasia Ivanova & Se Hee Kim, 2009. "Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach," Biometrics, The International Biometric Society, vol. 65(1), pages 307-315, March.
    3. Peter F. Thall & Hoang Q. Nguyen & Ralph G. Zinner, 2017. "Parametric dose standardization for optimizing two-agent combinations in a phase I–II trial with ordinal outcomes," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 66(1), pages 201-224, January.
    4. Drovandi, Christopher C. & McGree, James M. & Pettitt, Anthony N., 2013. "Sequential Monte Carlo for Bayesian sequentially designed experiments for discrete data," Computational Statistics & Data Analysis, Elsevier, vol. 57(1), pages 320-335.
    5. Jay Bartroff & Tze Leung Lai, 2011. "Incorporating Individual and Collective Ethics into Phase I Cancer Trial Designs," Biometrics, The International Biometric Society, vol. 67(2), pages 596-603, June.
    6. B. Nebiyou Bekele & Yisheng Li & Yuan Ji, 2010. "Risk-Group-Specific Dose Finding Based on an Average Toxicity Score," Biometrics, The International Biometric Society, vol. 66(2), pages 541-548, June.
    7. Peter F. Thall & Aniko Szabo & Hoang Q. Nguyen & Catherine M. Amlie-Lefond & Osama O. Zaidat, 2011. "Optimizing the Concentration and Bolus of a Drug Delivered by Continuous Infusion," Biometrics, The International Biometric Society, vol. 67(4), pages 1638-1646, December.
    8. Márcio A. Diniz & Sungjin Kim & Mourad Tighiouart, 2020. "A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Ordinal Toxicity Grades," Stats, MDPI, vol. 3(3), pages 1-18, July.
    9. Xiaobin Yang & Keying Ye, 2012. "A Phase I Dose-_finding Study Based on Polychotomous Toxicity Responses Toxicity issue is always a main concern in phase I study and it is commonly categorized to multiple grades. In this study, the c," Working Papers 0004, College of Business, University of Texas at San Antonio.
    10. Ying Yuan & Guosheng Yin, 2009. "Bayesian dose finding by jointly modelling toxicity and efficacy as time‐to‐event outcomes," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 58(5), pages 719-736, December.
    11. Yuxi Tao & Junlin Liu & Zhihui Li & Jinguan Lin & Tao Lu & Fangrong Yan, 2013. "Dose-Finding Based on Bivariate Efficacy-Toxicity Outcome Using Archimedean Copula," PLOS ONE, Public Library of Science, vol. 8(11), pages 1-6, November.
    12. Shenghua Fan & Bee Leng Lee & Ying Lu, 2020. "A Curve-Free Bayesian Decision-Theoretic Design for Phase Ia/Ib Trials Considering Both Safety and Efficacy Outcomes," Statistics in Biosciences, Springer;International Chinese Statistical Association, vol. 12(2), pages 146-166, July.
    13. Peter Müller & Don A. Berry & Andrew P. Grieve & Michael Krams, 2006. "A Bayesian Decision-Theoretic Dose-Finding Trial," Decision Analysis, INFORMS, vol. 3(4), pages 197-207, December.
    14. Guosheng Yin & Yisheng Li & Yuan Ji, 2006. "Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios," Biometrics, The International Biometric Society, vol. 62(3), pages 777-787, September.
    15. Chunyan Cai & Ying Yuan & Yuan Ji, 2014. "A Bayesian dose finding design for oncology clinical trials of combinational biological agents," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 63(1), pages 159-173, January.
    16. Murray Thomas A., 2017. "Ranking ultimate teams using a Bayesian score-augmented win-loss model," Journal of Quantitative Analysis in Sports, De Gruyter, vol. 13(2), pages 63-78, June.
    17. Haitao Pan & Ping Huang & Zuoren Wang & Ling Wang & Chanjuan Li & Jielai Xia, 2013. "A Novel Bayesian Seamless Phase I/II Design," PLOS ONE, Public Library of Science, vol. 8(9), pages 1-6, September.
    18. Sergei Leonov & Bahjat Qaqish, 2020. "Correlated endpoints: simulation, modeling, and extreme correlations," Statistical Papers, Springer, vol. 61(2), pages 741-766, April.
    19. Peter F. Thall & Hoang Q. Nguyen & Elihu H. Estey, 2008. "Patient-Specific Dose Finding Based on Bivariate Outcomes and Covariates," Biometrics, The International Biometric Society, vol. 64(4), pages 1126-1136, December.
    20. Christophe Le Tourneau & Hui K Gan & Albiruni R A Razak & Xavier Paoletti, 2012. "Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents," PLOS ONE, Public Library of Science, vol. 7(12), pages 1-3, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:bla:biomet:v:70:y:2014:i:2:p:389-397. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Wiley Content Delivery (email available below). General contact details of provider: http://www.blackwellpublishing.com/journal.asp?ref=0006-341X .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.